Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-label Trial Comparing VT3989 Versus Gemcitabine or Vinorelbine in Participants With Advanced Epithelioid Mesothelioma, Who Previously Received Platinum-Based Systemic Chemotherapy and Immunotherapy

NCT07824986 is registered in ClinicalTrials.gov with Vivace Therapeutics, Inc as lead sponsor.

NCT NCT07824986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-label Trial Comparing VT3989 Versus Gemcitabine or Vinorelbine in Participants With Advanced Epithelioid Mesothelioma, Who Previously Received Platinum-Based Systemic Chemotherapy and Immunotherapy
Lead sponsor
Vivace Therapeutics, Inc
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
January 1, 2031
Enrollment
350 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, pleural mesothelioma